Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic FibrosisContributed by: Business WireLogoTagsHealthGeneticsClinical TrialsResearchSciencePharmaceuticalBiotechnologyCystic Fibrosis